Sistema de Salut de Catalunya
Institut Català de la Salut
[de Castro MJ, Couce ML] Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Paediatrics, Santiago de Compostela University Clinical Hospital, 15704 Santiago de Compostela, Spain. IDIS, Health Research Institute of Santiago de Compostela, 15704 Santiago de Compostela, Spain. CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, 28029 Madrid, Spain. MetabERN, European Reference Network for Hereditary Metabolic Disorders, 33100 Udine, Italy. [Del Toro M] CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, 28029 Madrid, Spain. MetabERN, European Reference Network for Hereditary Metabolic Disorders, 33100 Udine, Italy. Servei de Neurologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERER, MetabERN, Barcelona, Spain. [Giugliani R] Medical Genetics Service, Gene Therapy Center, Medical Genetics Clinical Research Group, Biodiscovery Research Group, HCPA, Porto Alegre 90035-903, Brazil. Department of Genetics, UFRGS, Porto Alegre 91501-970, Brazil. DASA/GeneOne, São Paulo 04078-013, Brazil
Vall d'Hebron Barcelona Hospital Campus
2022-04-22T13:24:23Z
2022-04-22T13:24:23Z
2021-09
Virus adeno associat; Lentivirus; Vectors virals
Virus adenoasociado; Lentivirus; Vectores virales
Adeno-associated virus; Lentivirus; Viral vectors
The need for long-lasting and transformative therapies for mucopolysaccharidoses (MPS) cannot be understated. Currently, many forms of MPS lack a specific treatment and in other cases available therapies, such as enzyme replacement therapy (ERT), do not reach important areas such as the central nervous system (CNS). The advent of newborn screening procedures represents a major step forward in early identification and treatment of individuals with MPS. However, the treatment of brain disease in neuronopathic MPS has been a major challenge to date, mainly because the blood brain barrier (BBB) prevents penetration of the brain by large molecules, including enzymes. Over the last years several novel experimental therapies for neuronopathic MPS have been investigated. Gene therapy and gene editing constitute potentially curative treatments. However, despite recent progress in the field, several considerations should be taken into account. This review focuses on the state of the art of in vivo and ex vivo gene therapy-based approaches targeting the CNS in neuronopathic MPS, discusses clinical trials conducted to date, and provides a vision for the future implications of these therapies for the medical community. Recent advances in the field, as well as limitations relating to efficacy, potential toxicity, and immunogenicity, are also discussed.
This research received no external funding.
Article
Published version
English
Metabolisme, Errors congènits del - Tractament; Teràpia genètica; DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Metabolism, Inborn Errors::Carbohydrate Metabolism, Inborn Errors::Mucopolysaccharidoses; Other subheadings::Other subheadings::Other subheadings::/genetics; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Genetic Therapy; ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::alteraciones congénitas del metabolismo::trastornos congénitos del metabolismo de los carbohidratos::mucopolisacaridosis; Otros calificadores::Otros calificadores::Otros calificadores::/genética; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::terapia genética
MDPI
International Journal of Molecular Sciences;22(17)
https://doi.org/10.3390/ijms22179200
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
